Virpax reaches deal to settle litigation with Sorrento Therapeutics, Scilex Pharmaceuticals

The lawsuit alleged former Virpax CEO Anthony Mack breached the “restrictive covenants agreement” he entered into with Sorrento when he sold all of his shares in Scilex, a pain medicine developer, for about $12 million in 2016.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks